Stephen Worthley1, Randall Hendriks2, Matthew Worthley3, Alan Whelan2, Darren L Walters4, Robert Whitbourn5, Ian Meredith6. 1. Cardiovascular Investigation Unit, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia. Electronic address: stephen.worthley@adelaide.edu.au. 2. Cardiology Research Centre, Fremantle Hospital, Fremantle, Australia. 3. Cardiovascular Investigation Unit, Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia. 4. Department of Cardiology, Prince Charles Hospital, Brisbane, Australia and University of Queensland, Brisbane Australia. 5. Department of Cardiology, St Vincent's Hospital, Melbourne, Fitzroy, Australia. 6. Cardiovascular Research Centre, Monash Medical Centre, Clayton, Australia.
Abstract
BACKGROUND: Several studies investigated the combination of bare metal stents in the main branch and drug-eluting balloons in the side branch in bifurcation lesions, but data on the combination of drug-eluting stents and drug-eluting balloons are scarce. We aim to assess the feasibility of provisional stenting with an everolimus-eluting stent in the main branch and a paclitaxel-eluting balloon in the side branch. METHODS: In this prospective, multi-center study conducted in 5 Australian sites, 35 patients with bifurcation lesions were enrolled. Angiographic and intravascular ultrasound assessments were conducted at 9 months; clinical follow-up was conducted until 12 months. RESULTS: The primary endpoint, late lumen loss in the side branch measured by quantitative coronary angiography, was 0.10±0.43mm. No binary restenosis was observed. One patient died; 3 myocardial infarctions (one suspected and two in non-target vessels) and one target lesion revascularization occurred. No probable or definite stent thrombosis was observed. CONCLUSION: The combination of an everolimus-eluting stent in the main branch and a paclitaxel-eluting balloon in the side branch appears to be a safe, effective and novel treatment option for bifurcation lesions.
BACKGROUND: Several studies investigated the combination of bare metal stents in the main branch and drug-eluting balloons in the side branch in bifurcation lesions, but data on the combination of drug-eluting stents and drug-eluting balloons are scarce. We aim to assess the feasibility of provisional stenting with an everolimus-eluting stent in the main branch and a paclitaxel-eluting balloon in the side branch. METHODS: In this prospective, multi-center study conducted in 5 Australian sites, 35 patients with bifurcation lesions were enrolled. Angiographic and intravascular ultrasound assessments were conducted at 9 months; clinical follow-up was conducted until 12 months. RESULTS: The primary endpoint, late lumen loss in the side branch measured by quantitative coronary angiography, was 0.10±0.43mm. No binary restenosis was observed. One patient died; 3 myocardial infarctions (one suspected and two in non-target vessels) and one target lesion revascularization occurred. No probable or definite stent thrombosis was observed. CONCLUSION: The combination of an everolimus-eluting stent in the main branch and a paclitaxel-eluting balloon in the side branch appears to be a safe, effective and novel treatment option for bifurcation lesions.
Authors: William T Peverill; Alexander Incani; Stephen G Worthley; Yash Singbal; Paul J Garrahy; Andrew B McCann; Stephen V Cox; Peter T Moore; Richard Y Y Lim; Taufik Fetahovic; Gerard W Connors; Cindy Hall; Charmaine Sieg; Anthony C Camuglia Journal: Int J Cardiol Heart Vasc Date: 2020-09-25